Clinical trials: Overweight or Obese Adults
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo
The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss.
- Trial name
- NCT07757087
- Testing
- NNC0487-0111, LED
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.
- Trial name
- NCT06934408
- Testing
- HRS-5817 Injection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoarthritis, Overweight or Obesity
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have…
- Trial name
- ENLIGHTEN-4 (NCT07353931)
- Testing
- Eloralintide
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Obesity and Overweight, Moderately Obese
EXploratory Study on Postprandial Energy Metabolism
This exploratory, double-blinded clinical trial on 66 randomized adults aged 50 to 70 years with moderate overweight or obesity but considered metabolically healthy will consist of comparing metabolic and microbiota parameters…
- Trial name
- EXPEM (NCT06786052)
- Testing
- Probiotic
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Healthy Volunteers, Overweight or Obesity
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered…
- Trial name
- NCT07499050
- Testing
- RO7795081
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or…
- Trial name
- NCT05153590
- Testing
- Saxenda®
- Where
- Denmark
- Volunteers
- 269 people
- Sponsor
- Novo Nordisk A/S
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Obesity, Overweight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or…
- Trial name
- NCT06230523
- Testing
- Eloralintide
- Where
- 43 sites in United States
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S